Pharmaceutical - Daiichi Sankyo, Research

Filter

Current filters:

Daiichi SankyoResearch

Popular Filters

Sanford-Burnham and Daiichi Sankyo collaborate on novel cardiovascular-metabolic diseases drug targets

22-05-2014

USA-based Sanford-Burnham Medical Research Institute and Japanese drug major Daiichi Sankyo have entered…

Cardio-vascularDaiichi SankyoMetabolicsPharmaceuticalResearch

Daiichi Sankyo halts nimotuzumab Ph III trial in lung cancer

Daiichi Sankyo halts nimotuzumab Ph III trial in lung cancer

30-04-2014

Japanese drug major Daiichi Sankyo says that it has discontinued the Phase III clinical trial conducted…

Daiichi SankyonimotuzumabOncologyPharmaceuticalResearch

Astellas and Daiichi Sankyo share 400,000 compounds in research agreement

Astellas and Daiichi Sankyo share 400,000 compounds in research agreement

19-03-2014

Japanese drug majors Astellas Pharma and Daiichi Sankyo will form a compound library sharing partnership…

Astellas PharmaDaiichi SankyoJapanLicensingPharmaceuticalResearch

Daiichi Sankyo and UMN Pharma collaborate over norovirus vaccine

Daiichi Sankyo and UMN Pharma collaborate over norovirus vaccine

14-02-2014

Japanese drug companies Daiichi Sankyo and UMN Pharma have signed a collaborative research agreement…

Daiichi SankyoJapanLicensingPharmaceuticalResearchVaccines

Daiichi Sankyo files Savaysa for US approval; collaborates with Virtici and Celdara Medical

Daiichi Sankyo files Savaysa for US approval; collaborates with Virtici and Celdara Medical

10-01-2014

Japanese drug major Daiichi Sankyo has filed a New Drug Application for its investigational, oral, once-daily…

Cardio-vascularCeldara MedicalDaiichi SankyoedoxabanNorth AmericaPharmaceuticalRegulationResearchSavaysaUSAVirtici

Daiichi Sankyo's edoxaban shows comparable efficacy to warfarin in Phase III trial

Daiichi Sankyo's edoxaban shows comparable efficacy to warfarin in Phase III trial

20-11-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) says that its blood thinner edoxaban met the primary efficacy…

Asia-PacificCardio-vascularDaiichi SankyoedoxabanPharmaceuticalResearchWarfarin Sodium

Daiichi Sankyo partners in new open innovation business funding

18-09-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) and Mitsubishi UFJ Capital Co have agreed to launch a…

Asia-PacificDaiichi SankyoFinancialPharmaceuticalResearch

Pre-treatment with prasugrel - more risk, no benefit: ACCOAST

02-09-2013

In patients with non-ST-elevation acute coronary syndrome (NSTE- ACS), pre-treatment with the P2Y12 antagonist…

Cardio-vascularDaiichi SankyoEffientEli LillyPharmaceuticalprasugrelResearch

Positive Ph III results for Daiichi Sankyo's edoxaban in VTE

02-09-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) has released encouraging results from the global Phase…

Cardio-vascularDaiichi SankyoedoxabanLixianaPharmaceuticalResearch

Daiichi Sankyo's anti-clotting drug shows promise in Ph III CAD study

14-07-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) presented positive results of the PRASFIT-Elective Phase…

Cardio-vascularDaiichi SankyoEffientEli LillyPharmaceuticalprasugrelResearch

Daiichi Sankyo to support Phase I clinical study of anticoagulant activity reverser for edoxaban

25-04-2013

USA-based Perosphere and Japanese drug major Daiichi Sankyo(TYO: 4568) have entered into a clinical trial…

Cardio-vascularDaiichi SankyoedoxabanPER977PharmaceuticalResearch

MHLW joins Japan's first P-PP to facilitate R&D of new health technologies for the developing world

08-04-2013

The Japanese Ministry of Health, Labor and Welfare (MHLW) has said it supports the research and development…

Asia-PacificAstellas PharmaDaiichi SankyoEisaiFinancialHealthcarePharmaceuticalResearchShionogiTakeda PharmaceuticalsTropical diseases

Daiichi Sankyo returns rights to ArQule for global AKT program

03-04-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) has returned worldwide rights for the development and…

ARQ 092ARQ 197ArQuleDaiichi SankyoLicensingOncologyPharmaceuticalResearchtivantinib

Daiichi Sankyo updates on PRASFIT-Elective study, NDA filing

14-03-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) says that the follow-up period for the Phase III PRASFIT-Elective…

Asia-PacificAspirinCardio-vascularDaiichi SankyoEffientPharmaceuticalprasugrelRegulationResearch

Another disappointment with Daiichi Sankyo and ArQule's tivantinib

14-01-2013

US drug developer ArQule (Nasdaq: ARQL) saw its shares plunge 23% to $2.25 in premarket trading on Friday,…

ArQuleDaiichi SankyoOncologyPharmaceuticalResearchtivantinib

ArQule and Daiichi Sankyo drop tivantinib trial in NSCLC

03-10-2012

USA-based drug developer ArQule (Nasdaq: ARQL) saw its shares plunge 62% to $1.90 after, along with its…

ArQuleBiotechnologyDaiichi SankyoOncologyPharmaceuticalResearchtivantinib

Daiichi Sankyo to file prasugrel in Japan next year, following strong results

25-09-2012

Japanese drug major Daiichi Sankyo (TYO: 4568) has announced data from the PRASFIT-ACS study, a double-blind…

Asia-PacificCardio-vascularDaiichi SankyoPharmaceuticalprasugrelRegulationResearch

Anti-clotting drugs prasugrel and clopidogrel yield similar results

27-08-2012

The TRILOGY ACS study, the first trial to study patients with acute coronary syndrome who do not undergo…

Bristol-Myers SquibbCardio-vascularDaiichi SankyoEffientEli LillyPharmaceuticalPlavixResearchSanofi

Daiichi Sankyo and Terumo link up for vaccine development

27-02-2012

Drug major Daiichi Sankyo (TYO: 4568) and fellow Japanese company Terumo Corp (TYO: 4543) have entered…

Antibiotics and Infectious diseasesDaiichi SankyoPharmaceuticalResearchTerumoVaccines

Daiichi Sankyo to license ARQ 092 from ArQule, under joint AKIP research collaboration

11-11-2011

Japanese drug major Daiichi Sankyo (TSE 4568) says it has executed a license agreement with USA-based…

ArQuleDaiichi SankyoLicensingOncologyPharmaceuticalResearch

Daiichi Sankyo research exec points out “a lot of hype” around biomarkers

17-10-2011

Robert Beckman, executive director, clinical development oncology at Japanese drug major Daiichi Sankyo…

Daiichi SankyoOncologyPharmaceuticalResearch

Back to top